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TGF-b1 activates MAP kinase in human mesangial cells: A The pathogenic importance of transforming growth
possible role in collagen expression. factor-b (TGF-b) in glomerular disease has received con-
Background. Although the pathogenic relevance of trans- siderable attention and is supported by ample clinical
forming growth factor-b (TGF-b) to glomerular sclerosis has and experimental data [1, 2]. Overexpression of this cyto-
been established, the intracellular mechanisms by which TGF-b
kine has been observed in experimental models of glo-induces extracellular matrix accumulation are not fully under-
merulosclerosis such as anti–Thy-1 glomerulonephritisstood. We examined whether the mitogen-activated protein
(GN), antiglomerular basement membrane nephritis,(MAP) kinase pathway is involved in TGF-b1–induced colla-
gen expression by cultured human mesangial cells. and puromycin-induced nephrosis. In addition, human
Methods. The activation of MAP kinase pathways by TGF-b1 diseases such as IgA nephropathy, focal segmental glo-
was assessed by immunoblot with anti-phospho-ERK or -JNK merulosclerosis, lupus nephritis, diabetic nephropathy,
antibodies and by transfection of plasmids expressing pathway- and human immunodeficiency virus-associated nephrop-
specific transcription activators fused to the DNA-binding do- athy have been associated with TGF-b production [3–6].main of GAL4, as well as a GAL4 response element-luciferase
Transgenic mice overexpressing TGF-b develop severereporter gene. The role of MAP kinase was assessed using
glomerulosclerosis [7]. We and others have previouslybiochemical inhibitors and transiently expressed dominant neg-
reported that TGF-b could cause extracellular matrixative mutant constructs. The effects on TGF-b1–induced a1(I)
collagen expression were evaluated by Northern blot and by (ECM) accumulation by enhancing glomerular mesan-
activation of a transiently transfected a1(I) promoter-luciferase gial cell production of collagen and fibronectin [8–10],
reporter construct. suppressing the expression of ECM-degrading proteases
Results. ERK and JNK phosphorylation occurred 30 min- [11], and increasing the synthesis of ECM protease inhib-
utes and one hour, respectively, after TGF-b1 treatment. A
itors. Treatment with anti–TGF-b serum [12], decorin,biochemical blockade of the ERK pathway inhibited TGF-b1–
a natural inhibitor of TGF-b [13], or oligodeoxynucleo-induced a1(I) collagen expression. A dominant negative mu-
tides antisense to TGF-b [14] is reported to reduce excesstant of ERK1 but not of JNK decreased a1(I) gene promoter
deposition of ECM in glomeruli in the acute anti–Thy-1activation. Activation of the TGF-b–responsive p3TP-Lux con-
struct was partially inhibited by cotransfection of an ERK1 GN model. These reports support the hypothesis that
dominant negative mutant. TGF-b is a central mediator of the sclerosing process in
Conclusion. These data indicate that MAP kinase pathways diseased glomeruli.
can be activated by TGF-b1 in mesangial cells and that the Despite the wealth of data associating TGF-b with
ERK MAP kinase plays a role in TGF-b–stimulated collagen I
matrix accumulation, little information is available re-expression. Because we have shown previously that SMADs
garding the mechanism by which TGF-b stimulates thismediate TGF-b1–stimulated collagen I expression, our findings
process. The intracellular signals leading to increasedraise the possibility of interactions between the MAP kinase
ECM in mesangial cells are even less well understood. Inand the SMAD pathways.
contrast to most growth factors, which transduce signals
through receptor tyrosine kinases, constituents of the
TGF-b superfamily use serine/threonine kinase recep-Key words: transforming growth factor-b, mitogen activated protein
kinase, type I collagen, cytokine, sclerosing process. tors [15, 16]. Recently, a novel group of proteins, the
SMADs, has been shown to be specifically activated inReceived for publication February 16, 1999
response to TGF-b superfamily members [17, 18]. Uponand in revised form May 19, 1999
Accepted for publication June 7, 1999 binding of TGF-b to its receptor, Smad2 and Smad3 un-
dergo serine phosphorylation and, after associating with 1999 by the International Society of Nephrology
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Smad4, translocate to the nucleus. There, this heteromul- man-PDGF antibodies were purchased from Santa Cruz
timer regulates transcription of target genes by direct Biochemistry (Santa Cruz, CA, USA).
binding to promoter sequences and/or by association
with other transcription factors [19–22]. This regulation Cell culture and treatment
might also require interaction with coactivators such as Human mesangial cells were isolated from glomeruli
p300/CBP [23–25]. Recently, we have determined that by differential sieving of minced human renal cortex
human mesangial cells express SMAD proteins and that from anonymous surgery or autopsy specimens. Cells
these proteins are activated in response to TGF-b1 and were cultured with Dulbecco’s modified Eagle’s medium
participate in TGF-b1 stimulation of a2(I) collagen ex- (DMEM)/Ham’s F12 medium supplemented with 20%
pression [26]. heat-inactivated fetal bovine serum (FBS), glutamine,
In contrast to the TGF-b–specific SMAD pathway, penicillin/streptomycin, sodium pyruvate, HEPES buffer,
mitogen-activated protein (MAP) kinase pathways are and 8 mg/ml insulin (GIBCO BRL, Gaithersburg, MD,
more classically associated with growth factor stimulation USA) as previously described [8]. Cells were confirmed
of receptor tyrosine kinases. The MAP kinase pathway as mesangial by morphological criteria, by the absence
consists of several phosphorylation cascades, each of which
of staining for cytokeratin and factor VIII-related anti-
modulates different signaling events either alone or in
gen, and by the presence of a-smooth muscle actin. The
concert with other pathways [27, 28]. Among them, extra-
cells were mycoplasma free by the method of Chen [35].
cellular signal-regulated protein kinase (ERK) and c-Jun
Cells at passages 5 through 8 were grown to 80% conflu-N-terminal kinase (JNK) are the most extensively stud-
ence and were serum starved for 24 hours prior to treat-ied. Although their functions are typically associated with
ment if necessary. The cells were then treated with 1.0cell proliferative events for ERK or modulation of apopto-
ng/ml TGF-b1 in serum-free medium for various timesis and immune responses for JNK, it is now clear that
periods, following two-hour pretreatment with inhibitorsMAP kinases function in a more pleiotropic manner to
or neutralizing antibodies where noted.regulate a variety of cell functions.
Several groups have reported that TGF-b also could Mitogen-activated protein kinase activity and
activate MAP kinase pathways in certain cell lines [29–33]. signal transduction
In this study, we show that both the ERK and the JNK
In preliminary studies, we determined that MAP ki-pathways are activated by TGF-b1 in human mesangial
nase activity, as assessed by in vitro immune complexcells with resulting signal transduction. A blockade of
kinase activity, was comparable to results obtained bythe ERK pathway either by chemical treatment or by
evaluating MAP kinase activation, as assessed by West-overexpression of a dominant negative mutant inhibits
ern blotting with antiphospho-ERK or antiphospho-JNKTGF-b1–induced a1(I) collagen expression. The activa-
antibodies. We used this simpler assay subsequently.tion of p3TP-Lux, a commonly used TGF-b–responsive
Briefly, cells washed twice with ice-cold phosphate-buf-reporter construct that contains both AP-1 sites and a
fered saline (PBS) were lyzed on ice in RIPA buffer [50possible SMAD-responsive element [34], was suppressed
mm Tris/HCl, pH 7.5, 150 mm NaCl, 1% Nonidet P-40,by cotransfection of an ERK1 dominant negative mu-
0.5% deoxycholate, 0.1% sodium dodecyl sulfate (SDS)]tant. These results support a role for ERK MAP kinase
containing protease and phosphatase inhibitors [1 mmin TGF-b–stimulated collagen I synthesis and suggest a
phenylmethylsulfonyl fluoride (PMSF), 1 mm ethylenedi-possible interaction of the MAP kinase pathway with
aminetetraacetic acid (EDTA), 1 mg/ml leupeptin, 1 mmSMAD-mediated signaling initiated by TGF-b1.
sodium orthovanadate] and centrifuged at 18,000 g for
20 minutes at 48C. The samples, standardized for protein
METHODS content by Bradford Protein Assay (BioRad, Hercules,
Materials CA, USA), were prepared in Laemmli reducing buffer
[final concentrations: 50 mm Tris/HCl, pH 6.8, 2% SDS,Active, recombinant human TGF-b1 (R&D Systems,
10% glycerol, 0.1% bromophenol blue, 100 mm dithio-Minneapolis, MN, USA) was reconstituted as a 4 mg/ml
threitol (DTT)] and boiled for three minutes before load-stock solution in 4 mm HCl with 1 mg/ml bovine serum
ing. Samples electrophoresed through a 10% acrylamidealbumin (BSA). Recombinant human platelet-derived
gel were blotted onto Immobilon-P (PVDF) membranesgrowth factor (PDGF)-BB was purchased from R&D
(Millipore, Bedford, MA, USA) with a semidry blottingSystems. PD98059 (Calbiochem, San Diego, CA, USA)
unit (Fisher Scientific, Pittsburgh, PA, USA). Mem-was dissolved in dimethyl sulfoxide at 5 mm as a stock
branes were blocked with 5% BSA in Tris-buffered sa-solution. Antibodies were purchased from the following
line (TBS)-Tween (0.1%) overnight at 48C followed byvendors: antiphospho-ERK and anti-ERK-1 and -2 anti-
incubation with the primary antibodies for one hour atbodies, from Promega (Madison, WI, USA); antiphos-
pho-JNK, anti-JNK-1 and -2, and neutralizing antihu- room temperature. After washing with TBS-Tween three
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Fig. 1. Activation of mitogen-activated pro-
tein (MAP) kinases by transforming growth
factor-b1 (TGF-b1). Near-confluent human
mesangial cells were serum starved for 24
hours and treated with 1.0 ng/ml TGF-b1 for
the indicated time periods. (A) Cell lysates
were analyzed by immunoblot with antiphos-
pho-ERK1/2 antibody for ERK activation or
with anti-ERK1/2 antibody for protein expres-
sion. Insufficient data points were available to
perform statistical analysis for values at 15
minutes. (B) Immunoblot with antiphospho-
JNK1 and anti-JNK1 antibody. For each MAP
kinase, a representative blot is shown at the
top. The mean results of densitometric analy-
sis of three separate experiments are shown
at the bottom. Values in the graph are shown
as fold increase over control. *P , 0.05 com-
pared with control.
times for 10 minutes each, the blots were incubated with obtained from Dr. Y. Yamada (National Institutes of
Health, Bethesda, MA, USA). The equality of loadingthe secondary antibody conjugated to horseradish peroxi-
was confirmed by rehybridizing the blots with cDNAsdase for one hour at room temperature, and then immuno-
either for glyceraldehyde-3-phosphate dehydrogenasereactive bands were visualized by chemiluminescence re-
(GAPDH) obtained from Dr. L. Bruggeman (Mountaction (LuminoGLO Reagent and Peroxide; New England
Sinai School of Medicine, New York, NY, USA) or bo-Biolabs, Beverly, MA, USA). Immunoreactive bands
vine 28S ribosomal RNA provided by Dr. H. Sage (Uni-were scanned with an Arcus II Scanner (AGFA) in trans-
versity of Washington, Seattle, WA, USA).parency mode, and densitometric analysis was per-
formed using NIH Image 1.61 program for Macintosh. Transient transfection and luciferase assay
Cells were cultured in six-well plates at 5.0 3 104/wellRNA isolation and Northern blot
the day before transfection. DNAs (0.5 mg each) wereTen micrograms of total cellular RNA collected by
transfected using the Fugene6 (2 ml/1 mg of DNA; Roche/the single-step method of Chomczynski and Sacchi [36]
Boehringer Mannheim Biochemical, Indianapolis, IN,
were subjected to 1.2% agarose–1.1% formaldehyde gel USA) according to the manufacturer’s instructions.
electrophoresis and transferred to MagnaGraph nylon After 20 hours, cells were washed twice with PBS to
membranes (MSI, Westborough, MA, USA). The blots remove the DNAs and treated with 1.0 ng/ml TGF-b1
were prehybridized at 658C for two hours and then hy- in serum-free medium for an additional 24 hours. Cells
bridized overnight at 658C with 32P-labeled cDNAs (106 were harvested in reporter lysis buffer (Luciferase Bio-
cpm/ml) made with a Rediprime DNA labeling kit (Am- assay System; Promega), and after a single freeze/thaw
ersham Pharmacia Biotech, Piscataway, NJ, USA). The cycle, luciferase activity was read using a Berthold Lumat
blots were then washed with increasing stringency and luminometer. The data were standardized with b-galac-
exposed to x-ray film (Eastman Kodak, Rochester, NY, tosidase activity expressed by the cells using a b-Galac-
tosidase Enzyme Assay System (Promega).USA) at 2808C. The human a1(I) collagen cDNA was
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Fig. 1. (Continued)
ERK and JNK activities resulting from the transduced Plasmid constructs
signals were also determined by activation of Elk or p3TP-Lux was a generous gift from Dr. J. Massague
c-Jun, respectively, using an in vivo pathway reporting [34]. The human a1(I) collagen-luciferase construct con-
system (PathDetect; Stratagene, La Jolla, CA, USA). taining the sequence from 2806 to 1113 of the promoter
Cells were transfected with a plasmid that expresses ei- was constructed as follows: A Hind III fragment of the
ther the Elk- or the c-Jun-trans-activating domain fused plasmid pWS2.5/CAT [37] was subcloned into the Hind III
to the DNA binding region of yeast GAL4, along with a site of the pXP2 luciferase vector. The orientation of the
construct containing a GAL4 response element-luciferase promoter was confirmed by restriction mapping. Dominant
reporter. In addition, the cells were cotransfected with negative mutants of ERK1 and SEK were kindly provided
either a dominant negative mutant of ERK1 or SEK by Dr. M.H. Cobb [38] and Dr. J. Avruch [39], respec-
(JNK kinase) and with a constitutively active b-galactosi- tively. CMV-SPORT-b galactosidase as a control of trans-
dase expression vector as a control for transfection effi- fection efficiency was purchased from GIBCO-BRL.
ciency. After a 20-hour transfection, the cells were
Statistical analysisquiesced for 24 hours, stimulated by either 20% serum
or 1.0 ng/ml TGF-b1 for another 24 hours, and then Statistical differences between experimental groups
were determined by analysis of variance, and values oflysed for luciferase assay.
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P , 0.05 by Fisher’s PLSD test were considered signifi-
cant. The difference between the two comparative groups
was further analyzed by the unpaired Student’s t-test.
All of the analyses were performed using StatView 4.02
software program for the Macintosh.
RESULTS
Activation of mitogen-activated protein kinases by
transforming growth factor-b1
First, we evaluated whether TGF-b1 activates MAP
kinases in human mesangial cells. Both ERK and JNK
activation were assessed by either phosphorylation of
the kinases or in vitro kinase assay using myelin basic
protein (for ERK) or 1-81-c-Jun-GST fusion protein (for
JNK) as the substrate. Similar results were obtained by
either method (data not shown). As shown in Figure 1A,
ERK1 and ERK2 were activated beginning 30 minutes
after TGF-b1 treatment, with peak activation occurring
at four hours. JNK1 activation began at one hour and
lasted up to six hours (Fig. 1B). In some experiments,
increased JNK2 phosphorylation was also observed (data Fig. 2. Effect of cycloheximide treatment on transforming growth fac-
tor-b1 (TGF-b1)–induced mitogen-activated protein (MAP) kinase ac-not shown). The protein levels of both ERKs and JNKs
tivation. Quiesced cells were treated with 5 mg/ml cycloheximide (CHX)were not significantly affected by TGF-b1 treatment. for two hours and then stimulated with 1.0 ng/ml TGF-b1 for another
Thus, both ERK and JNK MAP kinases are activated two hours. Phosphorylation of ERK1/2 and JNK1 was evaluated by
immunoblot as described in Figure 1. Aliquots of the same lysates wereby TGF-b1 treatment of mesangial cells.
run in parallel and blotted either with anti–ERK1/2 or anti–JNK1-Because TGF-b1 has not been commonly associated antibody to check MAP kinase protein levels. Similar results were
with MAP kinase activation, we performed experiments obtained in three separate experiments.
to assess whether another protein(s) might mediate this
activation. Cells treated with cycloheximide (5 mg/ml)
showed no changes in either ERK or JNK activation at sive promoter-luciferase reporter construct and either
two hours (Fig. 2), suggesting that TGF-b1–induced ERK1 or SEK1 (JNK kinase) dominant negative mutants
MAP kinase activation is not mediated via synthesis of were transfected at the same time. The cells were then
an additional protein. TGF-b1 is also known to induce treated with 1.0 ng/ml TGF-b1 or 20% serum for 24 hours.
production and release of PDGF [40], which is a potent As shown in Figure 4A, the ERK1 dominant negative
stimulant of ERKs. To assess whether the activation of mutant blocked activation of Elk by TGF-b1, whereas
ERK by TGF-b1 might be mediated by PDGF release, the empty vector for the dominant negative mutant was
cells were preincubated with 10 mg/ml neutralizing anti- not inhibitory. In contrast, the ERK1 mutant did not
body to human PDGF or its control IgG for two hours inhibit activation of Elk by serum. These results suggest
prior to the treatment with TGF-b1 (Fig. 3). Neutraliza- that TGF-b1 induces Elk activity specifically through
tion of PDGF did not significantly affect the TGF-b1 ERK1, whereas serum induces Elk activity, either addi-
activation of ERK, suggesting that TGF-b1 activation tionally or exclusively, through other pathways. Activa-
of ERKs is not dependent on the release of PDGF. The tion of c-Jun also occurred after TGF-b1 stimulation of
efficacy of the neutralizing antibody was confirmed by its mesangial cells and was inhibited by the SEK1 dominant
ability to inhibit ERK activation by 5 ng/ml recombinant negative mutant (Fig. 4B). Activation of Elk or c-Jun by
human PDGF-BB. TGF-b1 does not require PDGF because anti-PDGF anti-
body did not prevent the induction of Elk activity in our
Functional assessment of TGF-b1–induced MAP experimental system (data not shown). These studies indi-
kinase signaling cate that both ERK and JNK are activated by TGF-b1
Next, we tested whether ERK and JNK MAP kinases in mesangial cells to transduce signals to the nucleus.
are functional in transducing signals to the nucleus in
Role of ERK- and JNK-mediated signaling inour system. Mesangial cells were transfected with plasmids
mesangial cell collagen expressioncontaining the transactivating domain of pathway-specific
transcription factors, Elk for ERK or c-Jun for JNK, fused Transforming growth factor-b1 induces mesangial cell
expression of type I collagen [8]. To determine whetherto the DNA binding domain of GAL4. A GAL4-respon-
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Fig. 3. Effect of neutralizing platelet-derived
growth factor (PDGF) on transforming
growth factor-b1 (TGF-b1)–induced ERK ac-
tivation. Ten mg/ml of neutralizing antibody
to human PDGF were added to the plates two
hours prior to the one-hour TGF-b1 treat-
ment. Control IgG had no effect on ERK ac-
tivity. ERK1/2 protein level was detected as
described in Figure 2. Representative blots
with antiphospho-ERK1/2 (top) and anti-
ERK1/2 (bottom) antibody are shown. The
result of densitometric analysis of two sepa-
rate experiments is shown in the graph. C,
control IgG; P, anti-PDGF antibody.
either the ERK or the JNK pathway is involved in TGF- able, we could not employ a similar approach to evaluate
a role for the JNK pathway in TGF-b1–induced collagenb1–induced collagen expression, we first evaluated the
effect of a biochemical inhibitor of ERK, PD98059, on expression. Instead, we assessed the possible involve-
ment of both ERK and JNK MAP kinases in TGF-TGF-b1–stimulated collagen mRNA expression. This sub-
stance specifically inhibits ERK by inhibiting the activity b1–induced collagen I gene transcription using a pro-
moter construct containing the sequence from 2806 toof MEK1 (MAP kinase kinase) at 10 mm. At higher doses,
the inhibitory effect becomes less specific. We treated the 1113 of the human a1(I) collagen (COL1 A1) gene
fused with a luciferase reporter gene. Promoter activitycells with PD98059 for two hours prior to 24-hour treat-
ment with TGF-b1. As shown in Figure 5A, 10 mm MEK was induced 2.1-fold by TGF-b1 in the cells transfected
with empty vector or the cells cotransfected with theinhibitor suppressed a1(I) collagen mRNA expression
induced by TGF-b1. No effect on GAPDH or ribosomal dominant negative mutant of SEK1 (Fig. 6). On the
other hand, the induction of a1(I) promoter activity wasRNA expression was seen, making a generalized effect
of PD98059 on cell function unlikely. To further confirm abrogated in the cells transfected with the ERK1 domi-
nant negative mutant construct. These data further sup-the specificity of this inhibitor for ERK activation, ERK
1/2 and JNK1 expression and phosphorylation were ex- port the hypothesis that the ERK pathway contributes
to TGF-b1–mediated collagen I gene transcription,amined. PD98059 specifically inhibits ERK1/2 phosphor-
ylation, whereas neither JNK1 phosphorylation nor pro- whereas the JNK pathway is not involved.
tein levels of MAP kinases are affected (Fig. 5B). These
Interaction of MAPK signaling with the SMAD signalresults confirm the specificity of the inhibitor and support
transduction pathwaythat the ERK pathway contributes to the TGF-b1–
induced increase in a1(I) collagen mRNA expression. Recently, our laboratory has shown that the TGF-b–
specific SMAD signaling pathway is present in mesangialAs no biochemical inhibitor of JNK is currently avail-
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Fig. 4. Activation of the transcription factors Elk and c-Jun by transforming growth factor-b1 (TGF-b1). Cells were transfected with a plasmid
that expresses an activation domain of either Elk or c-Jun linked to the DNA binding region of yeast GAL4, along with a GAL4-luciferase reporter
construct. In addition, the cells were cotransfected with a dominant negative mutant of either ERK1 or SEK1 or their corresponding empty vectors
and with a constitutively active b-galactosidase expression vector as a control for transfection efficiency. Values are the means 6 sem of luciferase
activity standardized by b-galactosidase activity from triplicate samples. (A) Elk activity was induced by either 20% serum or 1.0 ng/ml TGF-b1
for 24 hours. (B) c-Jun activity was induced by TGF-b1. Symbols are: (h) unstimulated; (j) stimulated; †P , 0.05; *P , 0.01, by unpaired
Student’s t-test.
cells and mediates a2(I) collagen gene transcription [26]. DISCUSSION
The observation in this study suggests that blocking ERK The accumulation of ECM is a common event in the
activation also inhibits TGF-b–stimulated collagen gene progression of glomerular disease. Evidence for overex-
transcription. Therefore, we performed experiments to pression of TGF-b in the sclerotic kidney and the profi-
brotic actions of this cytokine has suggested its impor-evaluate the potential interaction between the ERK and
tance in sclerosing renal disease [1, 2]. However, theSMAD pathways. Cells were cotransfected with the TGF-b–
cellular mechanisms by which TGF-b exerts its effectsresponsive p3TP-Lux construct along with dominant
have not been fully elucidated. In this study, we addressednegative mutants of MAP kinases or their corresponding
the possible involvement of MAP kinase pathways inempty vectors. A blockade of the ERK pathway reduced
TGF-b–induced signaling. Both the ERK and the JNKluciferase activity from 9.1-fold to 4.1-fold, a 60% reduc-
pathways were activated by TGF-b1 and proved to betion in the TGF-b1–induced increase over basal activity
functional in transducing signals to the nucleus. A bio-
(Fig. 7). In contrast, transfection of the SEK1 dominant chemical blockade of ERK activation inhibited TGF-b1–
negative mutant to block JNK activity did not affect induced collagen mRNA expression. Inhibition of ERK,
TGF-b–induced luciferase activity. Cotransfection of the but not JNK, by a dominant negative mutant construct
ERK1 dominant negative mutant did not affect basal similarly inhibited the increase in a1(I) collagen gene
luciferase activity (data not shown). These data suggest promoter activity induced by TGF-b1. Blockade of the
a possible interaction between the ERK and the SMAD ERK pathway also attenuated but did not completely
abrogate the activation of p3TP-Lux, a commonly usedpathways.
Fig. 5. (A) Effect of the MEK inhibitor,
PD98059, on TGF-b1–induced a1(I) collagen
mRNA expression. Cells quiesced by serum
starvation were pretreated with the indicated
concentrations of PD98059 or vehicle (0.5%
dimethyl sulfoxide) for two hours and then
stimulated with 1.0 ng/ml TGF-b1 for 24 hours.
a1(I) collagen mRNA levels were assessed by
Northern blotting, and the same blots were
stripped and reprobed for GAPDH and 28S
rRNA as loading control. (Top) Representa-
tive blots. (Bottom) Densitometric analysis of
four separate experiments, comparing the re-
sults in the presence and absence of 10 mm
PD98059. Values are expressed as fold in-
crease with TGF-b1 treatment after correction
for loading. P , 0.05. (B) Effect of PD98059
on MAP kinase activation by TGF-b1. Cells
pretreated with 10 mm PD95058 were treated
with 1.0 ng/ml TGF-b1 for 60 minutes. Phos-
phorylation of ERK1/2 or JNK1 and their pro-
tein levels were examined by immunoblot as
described in Figure 2.
TGF-b–responsive reporter gene, suggesting the exis-
tence of cross-talk between MAP kinase and SMAD
pathways in TGF-b–stimulated cells.
Recent studies have characterized the role of the
SMAD pathway in TGF-b signaling [15, 17, 18]. In addi-
tion, several reports have suggested that classic MAP
kinase pathways also may be activated by TGF-b [29–33].
However, results have varied depending on the cell lines
and the culture conditions used. Huwiler and Pfeilschif-
ter reported that TGF-b2 stimulates ERK activity in rat
mesangial cells [29]. In our study, both the ERK and
the JNK pathways were activated by TGF-b1 in human
mesangial cells. Relatively delayed activation of the
ERKs and the JNKs suggests that this activation repre-
sents an indirect process. In addition, the activation of
ERKs consistently preceded that of JNKs. Although the
significance of this difference in timing of activation re-
mains uncertain, we have at least ruled out the involve-
ment of new protein synthesis and/or release of PDGF
in TGF-b1–stimulated MAP kinase activation. Our data
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Fig. 7. Effect of inhibiting mitogen-activated protein (MAP) kinases
on transforming growth factor-b1 (TGF-b1)–induced p3TP-Lux activ-Fig. 6. Effect of blocking MAP kinase activity on a1(I) collagen pro-
ity. p3TP-Lux, along with either ERK1 or SEK1 dominant negativemoter activity induced by TGF-b1. Cells were transfected with 0.5
mutants or their corresponding empty vectors (0.5 mg each), was trans-mg of the ERK1 or SEK1 dominant negative mutants (j) or their
fected into mesangial cells. The cells were stimulated with 1.0 ng/mlcorresponding empty vectors (h) for 20 hours. Promoter activity was
TGF-b1 for 24 hours, and luciferase activity and b-galactosidase expres-assessed after 24 hours of treatment with 1.0 ng/ml TGF-b1. Values
sion were determined. The fold induction of p3TP-Lux activity is shownrepresent the means 6 sem of three independent experiments. The fold
as the means 6 sem of three independent experiments. Luciferaseinduction of luciferase activity by TGF-b1 was analyzed after normaliza-
activity was normalized for b-galactosidase expression. *P , 0.05. NS,tion of each response for b-galactosidase expression. *P , 0.05. NS,
not significant.not significant.
to gene promoter sequences [19, 20], whereas in others,defining functional activation of the ERK and the JNK
the SMAD complex appears to associate with other tran-pathways permit consideration of a physiological role
scription factors [21, 22, 45]. Thus, possible cross-talkfor MAP kinases in the response of human mesangial
between the ERK and SMAD pathways could occurcells to TGF-b1.
by (a) association of ERK-induced transcription factorsThe mechanisms regulating collagen expression are
with SMADs and other coactivators to form transcrip-not fully understood. In a previous study, we found that
tion regulatory complexes, (b) separate binding of tran-enhanced production of mesangial cell a1(I) and a2(I)
scription factors activated by ERKs and SMADs to sitescollagen by TGF-b1 results from increased gene tran-
on the promoter of the target gene, or (c) synergy be-scription rather than from stabilization of mRNA [26].
tween the ERK and SMAD pathways prior to their inter-Several groups have reported the importance of AP-1
action with the target gene.sites in a1(I) collagen gene expression [41], whereas oth-
Recently, de Caestecker et al showed that hepaticers have emphasized Sp1 [42] or NF-1 [43] sites, either of
growth factor and epidermal growth factor, which acti-which could be activated through MAP kinase pathways.
vate the Ras/Raf-1/MAP kinase pathway through theirThese results suggest that the ERK pathway plays a role
receptor tyrosine kinases, can also use the SMAD-medi-in collagen gene regulation. Recently, we and others
ated pathway [46]. In this study, we conversely demon-have reported a role for the SMAD pathway in collagen
strated that TGF-b1, which principally uses serine/threo-gene transcription as well [26, 44]. Because inhibition of
nine receptor kinase and the SMAD pathway, alsoERKs and SMADs each resulted in the reduction of
activates the MAP kinase pathway. These pathways arecollagen expression or promoter activity, the data sug-
shown in Figure 8. Growth factors activate receptor tyro-gest that both ERKs and SMADs may be required for
sine kinases, which transduce signals to the nucleusTGF-b1–induced type I collagen expression.
through MEK and ERK. Receptor tyrosine kinases alsoERK blockade reduced TGF-b1–induced activity of
may activate JNKs. Although TGF-bs have been reportedp3TP-Lux, a construct commonly used to characterize
to activate JNKs through TAB [47] and TAK [31], multi-TGF-b/SMAD signaling [34]. MAP kinase activation by
ple levels of interaction are possible among these path-TGF-b1 and partial suppression of p3TP-Lux activity by
ways. These could be stimulatory or inhibitory. For ex-the ERK1 dominant negative mutant suggest supple-
ample, Kretzschmar, Doody, and Massague reportedmental or synergistic participation of the ERK pathway
that ERK2 activated by epidermal growth factor or byin SMAD-mediated TGF-b1 signaling events in mesan-
transfecting active MEK1 with recombinant ERK2 pre-gial cells. The nature of this interaction is not certain.
In some cases, SMADs have been shown to bind directly vents nuclear translocation of Smad1 by phosphorylating
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In summary, our results support the involvement of
the ERK MAP kinase pathway in TGF-b1–induced a1(I)
collagen expression in human mesangial cells. Because
JNKs are activated as well, it is apparent that our findings
address only several of many possible effects of TGF-b1.
The activation of multiple pathways may account for the
pleiotropic effects of TGF-bs on mesangial cells. Further
investigation of the roles of these pathways in mesangial
cell function will elucidate additional potential roles for
TGF-bs in progressive glomerular disease.
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